Stage IV NSCLC: pre-diagnosis statin use linked to improved survival

Access to the full content of this site is available only to registered healthcare professionals. Register to read more
Takeaway
  • Statin drugs appear to have an anticancer effect in advanced lung cancer; this has already been observed in other cancer types.
Study design
  • Retrospective database study using the Surveillance, Epidemiology and End Results registry linked to Medicare claims to identify 5118 patients  65 y of age diagnosed with stage IV non-small cell lung cancer (NSCLC) between 2007 and 2009.
  • Survival of patients receiving vs not receiving statins before diagnosis was compared.
Key results
  • 27% of patients received statins at time of lung cancer diagnosis.
  • Median survival for the statin group was 7 vs 4 mo for nonstatin users (P<.001).
  • Propensity score analyses showed statin use was associated superior OS (HR, 0.76; 95% CI, 0.73-0.79) and lung c...